IMPACT OF EVOLOCUMAB THERAPY IN PATIENTS WITH DISCORDANCE BETWEEN LDL-C AND LDL-P
نویسندگان
چکیده
منابع مشابه
LDL pattern and correlation between LDL size and HDL-C, Triglyceride in type II diabetic patients compared with normal individuals
Introduction: Low density lipoprotein particles are non homogenous in terms of their density and composition. Type B pattern is characterized by predominance of small dense LDL particles. Investigations indicate that small dense LDL is associated with an increased risk of coronary artery disease (CAD). This study is designed to recognize additional effective parameter which could perhaps cont...
متن کاملDiscordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.
BACKGROUND Low-density lipoprotein cholesterol (LDL-C) is the traditional measure of risk attributable to LDL. Non-high-density lipoprotein cholesterol (NHDL-C), apolipoprotein B (apoB), and LDL particle number (LDL-P) are alternative measures of LDL-related risk. However, the clinical utility of these measures may only become apparent among individuals for whom levels are inconsistent (discord...
متن کاملCost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost-effective in the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic CVD (ASCVD) with or wit...
متن کاملEvolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate the feasibility of home-use administration. Two clinical studies enrolled patients with hypercholesterolemia or mixed dyslipidemia on statin therapy and with/without e...
متن کاملEffect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. DESIGN, SETTING, AND PATIENTS Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled study...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2017
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(17)35107-0